New research shows the benefits of the smoking cessation drug Chantix outweigh its risks. Studies, sponsored by the FDA, show Chantix does not increase a person's risk of psychiatric hospitalization. The drug greatly increases a smoker's odds of quitting. In a statement, the FDA says the current Chantix label warning of possible behavior changes, depression, and suicidal thoughts is appropriate and no stronger warnings are needed. Pfizer, the manufacturer of Chantix, is conducting their own studies looking at psychiatric risks of the drug, and should have results in about five years. Chantix helps block nicotine receptors in the brain, which will take away the pleasurable effects of smoking.
Copyright 2011 KCBD. All rights reserved